Dickkopf-1 Is Associated with Periarticular Bone Loss in Patients with Rheumatoid Arthritis*

Berit Grandaunet, Silje Watterdal Syversen, Mari Hoff, Glenn Haugeberg, Désirée van der Heijde, Tore K. Kvien, Therese Standal

Centre of Excellence for Molecular Inflammation Research, Trondheim, Norway..
Depart- ment of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway;.
Department of Rhe- umatology, Leiden University Medical Centre, Leiden, The Netherlands;.
Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway;.
KG Jebsen Center for Myeloma Research and Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway;.

DOI: 10.4236/ojra.2013.34033                

Abstract

Objective: To examine whether cytokines shown to suppress osteoblasts, Dickkopf-1 (DKK1) and hepatocyte growth factor (HGF), are associated with periarticular bone loss in rheumatoid arthritis (RA). Methods: RA patients with short disease duration were prospectively followed and hand bone mineral density was assessed by digital X-ray radiogrammetry (DXR) at baseline and after 1, 2 and 5 years. Plasma samples collected at baseline from 136 of the included patients were analyzed for HGF and DKK1. Group comparisons, correlation analyses and multivariate analyses were performed to evaluate the relationship between baseline cytokine levels and DXR-BMD. Results: Patients with hand bone loss after 1 year had significantly higher baseline plasma levels of DKK1 than patients without bone loss. Patients with periarticular bone loss after 2 and 5 years had significantly higher baseline plasma levels of HGF. Baseline DKK1 but not HGF levels were independently associated with periarticular bone loss after 1 year. Conclusion: High serum levels of DKK1 are weakly but independently associated with periarticular bone loss in RA. The importance of DKK1 and HGF for loss of periarticular bone needs to be defined in future studies.

Keywords

Rheumatoid Arthritis; Osteoporosis; Osteoblast; DKK1; HGF

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	M. Hoff, G. Haugeberg, S. Odegard, S. Syversen, R. Landewe, H. D. van der and T. K. Kvien, “Cortical Hand Bone Loss after 1 Year in Early Rheumatoid Arthritis Predicts Radiographic Hand Joint Damage at 5-Year and 10-Year Follow-Up,” Annals of the Rheumatic Diseases, Vol. 68, No. 3, 2009, pp. 324-329. http://dx.doi.org/10.1136/ard.2007.085985
[2]	G. Schett, “Cells of the Synovium in Rheumatoid Arthritis. Osteoclasts,” Arthritis Research & Therapy, Vol. 9, No. 1, 2007, p. 203. http://dx.doi.org/10.1186/ar2110
[3]	N. C. Walsh and E. M. Gravallese, “Bone Remodeling in Rheumatic Disease: A Question of Balance,” Immunological Reviews, Vol. 233, No. 1, 2010, pp. 301-312. http://dx.doi.org/10.1111/j.0105-2896.2009.00857.x
[4]	D. Diarra, M. Stolina, K. Polzer, J. Zwerina, M. S. Ominsky, D. Dwyer, A. Korb, J. Smolen, M. Hoffmann, C. Scheinecker, H. D. van der, R. Landewe, D. Lacey, W. G. Richards and G. Schett, “Dickkopf-1 Is a Master Regulator of Joint Remodeling,” Nature Medicine, Vol. 13, No. 2, 2007, pp. 156-163. http://dx.doi.org/10.1038/nm1538
[5]	M. M. Matzelle, M. A. Gallant, K. W. Condon, N. C. Walsh, C. A. Manning, G. S. Stein, J. B. Lian, D. B. Burr and E. M. Gravallese, “Resolution of Inflammation Induces Osteoblast Function and Regulates the Wnt Signaling Pathway,” Arthritis and Rheumatism, 2011.
[6]	T. Standal, N. Abildgaard, U. M. Fagerli, B. Stordal, O. Hjertner, M. Borset and A. Sundan, “HGF Inhibits BMP-Induced Osteoblastogenesis: Possible Implications for the Bone Disease of Multiple Myeloma,” Blood, Vol. 109, No. 7, 2007, pp. 3024-3030.
[7]	T. Kawasaki, Y. Niki, T. Miyamoto, K. Horiuchi, M. Matsumoto, M. Aizawa and Y. Toyama, “The Effect of Timing in the Administration of Hepatocyte Growth Factor to Modulate BMP-2-Induced Osteoblast Differentiation,” Biomaterials, Vol. 31, No. 6, 2010, pp. 1191-1198. http://dx.doi.org/10.1016/j.biomaterials.2009.10.048
[8]	E. Tian, F. Zhan, R. Walker, E. Rasmussen, Y. Ma, B. Barlogie and J. D. Shaughnessy Jr., “The Role of the Wnt-Signaling Antagonist DKK1 in the Development of Osteolytic Lesions in Multiple Myeloma,” New England Journal of Medicine, Vol. 349, No. 26, 2003, pp. 2483-2494. http://dx.doi.org/10.1056/NEJMoa030847
[9]	D. M. van der Heijde, “Radiographic Imaging: The ‘Gold Standard’ for Assessment of Disease Progression in Rheumatoid Arthritis,” Rheumatology, Vol. 39, No. S1, 2000, pp. 9-16. http://dx.doi.org/10.1093/oxfordjournals.rheumatology.a031496
[10]	B. Grandaunet, S. W. Syversen, M. Hoff, A. Sundan, G. Haugeberg, H. D. van der, T. K. Kvien and T. Standal, “Association between High Plasma Levels of Hepatocyte Growth Factor and Progression of Radiographic Damage in the Joints of Patients with Rheumatoid Arthritis,” Arthritis and Rheumatism, Vol. 63, No. 3, 2011, pp. 662-669. http://dx.doi.org/10.1002/art.30163
[11]	L. M. Smedstad, T. K. Kvien, T. Moum and P. Vaglum, “Life Events, Psychosocial Factors, and Demographic Variables in Early Rheumatoid Arthritis: Relations to One-Year Changes in Functional Disability,” Journal of Rheumatology, Vol. 22, No. 12, 1995, pp. 2218-2225.
[12]	F. C. Arnett, S. M. Edworthy, D. A. Bloch, D. J. Mc-Shane, J. F. Fries, N. S. Cooper, L. A. Healey, S. R. Kaplan, M. H. Liang, H. S. Luthra, et al., “The American Rheumatism Association 1987 Revised Criteria for the Classification of Rheumatoid Arthritis,” Arthritis and Rheumatism, Vol. 31, No. 3, 1988, pp. 315-324. http://dx.doi.org/10.1002/art.1780310302
[13]	S. W. Syversen, P. I. Gaarder, G. L. Goll, S. Odegard, E. A. Haavardsholm, P. Mowinckel, D. van der Heijde, R. Landewe and T. K. Kvien, “High Anti-Cyclic Citrullinated Peptide Levels and an Algorithm of Four Variables Predict Radiographic Progression in Patients with Rheumatoid Arthritis: Results from a 10-Year Longitudinal Study,” Annals of the Rheumatic Diseases, Vol. 67, No. 2, 2008, pp. 212-217. http://dx.doi.org/10.1136/ard.2006.068247
[14]	Q. Wen, L. Zhou, C. Zhou, M. Zhou, W. Luo and L. Ma, “Change in Hepatocyte Growth Factor Concentration Promote Mesenchymal Stem Cell-Mediated Osteogenic Regeneration,” Journal of Cellular and Molecular Medicine, 2011.
[15]	K. Yukioka, M. Inaba, Y. Furumitsu, M. Yukioka, T. Nishino, H. Goto, Y. Nishizawa and H. Morii, “Levels of Hepatocyte Growth Factor in Synovial Fluid and Serum of Patients with Rheumatoid Arthritis and Release of Hepatocyte Growth Factor by Rheumatoid Synovial Fluid Cells,” Journal of Rheumatology, Vol. 21, No. 12, 1994, pp. 2184-2189.
[16]	A. E. Koch, M. M. Halloran, S. Hosaka, M. R. Shah, C. J. Haskell, S. K. Baker, R. J. Panos, G. K. Haines, G. L. Bennett, R. M. Pope and N. Ferrara, “Hepatocyte Growth Factor. A Cytokine Mediating Endothelial Migration in Inflammatory Arthritis,” Arthritis and Rheumatism, Vol. 39, No. 9, 1996, pp. 1566-1575. http://dx.doi.org/10.1002/art.1780390917